Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | CASP3 | P42574 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | F2R | P25116 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1461879 | 0.84 | CYP3A4 (0.65) | TERTMAPTNPC1CASP3RAB9A | |
| SCHEMBL10323936 | 0.81 | NPC1 (0.62) | TERTMAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL15597435 | 0.79 | RAB9A (0.56) | MAPTNPC1CASP3RAB9ASENP7 | |
| SCHEMBL13254952 | 0.79 | SMN1; SMN2 (0.53) | MAPTNPC1RAB9AMAPK14 | |
| SCHEMBL11895500 | 0.77 | KMT2A (0.69) | MAPTNPC1RAB9AMAPK14ALDH1A1 | |
| SCHEMBL3868858 | 0.75 | MAPT (0.73) | MAPTNPC1RAB9AMAPK14ALDH1A1 | |
| SCHEMBL11573244 | 0.75 | ALDH1A1 (0.64) | TERTMAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL22529434 | 0.75 | L3MBTL1 (0.67) | MAPTNPC1RAB9AALDH1A1ALOX15 | |
| SCHEMBL14432792 | 0.74 | KDM4E (0.51) | MAPTNPC1RAB9AMAPK14ALDH1A1 | |
| SCHEMBL16942489 | 0.73 | NPC1 (0.50) | MAPTNPC1CASP3RAB9ASENP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012098065-A1 | PYRIDO PYRIMIDINES FOR USE AS DYRK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | WO | disclosed |
| US-20120184542-A1 | PYRIDO PYRIMIDINES | ANDERSON KEVIN (US) | 2012-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184542-A1 | PYRIDO PYRIMIDINES | TYMS, TYMP, DPYD | TERT 559/4885MAPT 34/4885NPC1 1780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.